Novel therapeutic interventions for allergic rhinitis

Abstract

Allergic rhinitis is a high-prevalence disease, affecting 10 – 20% of the general population. Allergic rhinitis is sustained by an IgE-mediated reaction and by a complex inflammatory network of cells, mediators and cytokines that becomes chronic when exposure to allergen persists. A T_H2-biased immune response is the background of the allergic inflammation. The current therapeutic strategy is mainly based on drugs (antihistamines, nasal corticosteroids, cromones and decongestants) and allergen immunotherapy. Drugs are (overall) effective in controlling symptoms but do not modify the immune background that leads to allergic inflammation and safety concerns may be present, especially for prolonged treatments. Immunotherapy can modify the allergic response but there is still room for improvement. Nowadays, several approaches are under investigation to optimise the management of allergic rhinitis. On one hand, new drugs and antimediators are being developed. On the other hand, attempts are being made to selectively block relevant signal pathways of allergic reaction. Finally, one of the major goals is to modify the T_H2-biased immune response by improving the characteristics and modes of action of allergen immunotherapy.

Keywords::

• allergen-specific immunotherapy
• allergic rhinitis
• antihistamines
• corticosteroids
• immune response
• monoclonal antibodies

Notes